Advertisement


Linda J. Burns, MD, on CAR T-Cell Therapy in ALL

2014 ASH Annual Meeting

Advertisement

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 380, “T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long-Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL,” presented by Stephan A. Grupp, MD, PhD.


Time: 1:26



Related Videos

Leukemia

Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 797,

Leukemia

Hagop Kantarjian, MD, on CAR T Cells in Relapsed/Refractory ALL

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 380,

Myelodysplastic Syndromes

Alan F. List, MD, on the CC-5013-MDS-005 Study

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 409, “Efficacy and ...

Lymphoma

Laurie Sehn, MD, on Brentuximab Vedotin in Diffuse Large B-Cell Lymphoma With Undetectable CD30

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 629, “Brentuximab Vedotin Monotherapy in ...

Leukemia

Linda J. Burns, MD, on the BLAST Study

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 379,

Advertisement

Advertisement



Advertisement